Last reviewed · How we verify
CAPOX 3 month
Capecitabine is a thymidylate synthase inhibitor.
Capecitabine is a thymidylate synthase inhibitor. Used for Colorectal cancer, Breast cancer, Stomach cancer.
At a glance
| Generic name | CAPOX 3 month |
|---|---|
| Sponsor | NRG Oncology |
| Drug class | Antimetabolite |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Capecitabine is a prodrug that is converted to 5-fluorouracil (5-FU) in the body, which then inhibits thymidylate synthase, leading to the disruption of DNA synthesis and cell death in rapidly dividing cancer cells.
Approved indications
- Colorectal cancer
- Breast cancer
- Stomach cancer
Common side effects
- Hand-foot syndrome
- Diarrhea
- Fatigue
Key clinical trials
- Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity (PHASE2, PHASE3)
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (PHASE2, PHASE3)
- Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial (NA)
- Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy (PHASE3)
- Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test (PHASE3)
- COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer (EARLY_PHASE1)
- Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAPOX 3 month CI brief — competitive landscape report
- CAPOX 3 month updates RSS · CI watch RSS
- NRG Oncology portfolio CI